디지털 바이오마커 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 임상 업무별, 치료 영역별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Digital Biomarkers Market Growth & Trends:

The global digital biomarkers market size is expected to reach USD 13.97 billion by 2030, growing at a CAGR of 22.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising adoption of mobile applications & devices related to healthcare, and rising awareness regarding the wide therapeutic applications, increased utilization of smartphones, and the introduction of novel wearable technologies. According to Accenture Health and Life Sciences Experience Survey in 2021, 26% of the people living in the U.S. experienced enhanced access to healthcare services with the adoption of healthcare applications and devices.

Further, governmental organizations have expressed interest in creating digital biomarker-based medication due to the significant hardship brought on by the Covid-19 outbreak. For instance, in March 2022, AstraZeneca teamed up with UK-based medical technology company Huma Therapeutics to develop Software as a Medical Device (SaMD) companion applications for a range of therapeutic diseases. These applications combined predictive algorithms, digital biomarkers, and real-world data.

The rising cost of drug research, combined with its low relative success rate, is fuelling rapid creation of digital biomarkers (DBMs). DBMs in this field assist in focusing on particular decentralized clinical study areas, including early-onset Alzheimer's or dementia, thereby lowering the time, failure rate of drug development, and cost. According to a blog post by a digital solutions company called healthxl, the Digital Medicine Society (DiME) lately brought together top pharmaceutical companies, including Eli Lilly, Merck, and Biogen, to ascertain a set of core standard digital endpoints for dementia and Alzheimer's disease. This was done to solve the issue of assessing the efficacy of new therapies in human subjects as well as to reduce time & money spent on research and development of new remedies.

Regional governments across the globe are supporting the adoption of biomarkers by conducting awareness programs and investing in the development of digital health. According to an article published by the UC Davis School of Medicine in 2022, the Digital Health Equity Program conducted by UC Davis Health received funding of USD 1.7 million from the federal government. This government funding is expected to contribute to the development of a regional digital public health platform capable of enhancing access to healthcare facilities for vulnerable populations in Northern California and Sacramento.

Emerging players, such as AliveCor Inc, Empatica, Inc., Huma, and VivoSense, are adopting strategies such as acquisitions, collaborations, partnerships, and new product launches is anticipated to drive the market growth over the forecast period. For instance, in January 2023, Huma, a digital health company, announced the acquisition of Alcedis to expand its capabilities in the digital clinical trial space. The goal of this acquisition is to develop healthcare solutions across various stages of development processes.

Digital Biomarkers Market Report Highlights:

• Based on type, wearables held the largest market share of 39.5% in 2023, owing to the emergence of new wearables for healthcare purposes. It is anticipated that the market demand for new wearable devices is expected to increase because of government authorities approving new wearable devices
• Based on clinical practice, the diagnosis digital biomarkers held the largest market share of 32.4% in 2023. Diagnosis digital biomarkers are quantifiable indicators of health conditions or diseases, derived from digital technologies such as wearables, mobile apps, and medical devices. They enable early detection, accurate diagnosis, and personalized treatment by analyzing physiological, behavioral, biochemical, imaging, and patient-reported data. These innovative tools contribute to the advancement of healthcare by improving patient outcomes and facilitating remote monitoring and disease management
• Based on therapeutic area,the cardiovascular disease segment dominated the market with a share of 19.8% in 2023, owing to the growing number of therapeutic applications and increasing incidences of cardiovascular disorders globally
• Based on end use, the healthcare companies held the largest market share of 50.1% in 2023, owing to the fact that healthcare companies have been working toward integrating digital measurements across the spectrum of clinical care & research
• North America dominated the market and accounted for a revenue share of 58.4% in 2023, owing to the strong presence of leading market players, significant product launches, and an increase in investments in the R&D biomarkers

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Clinical Practice
  • 1.2.3. Therapeutic Area
  • 1.2.4. End User
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Clinical practice outlook
  • 2.2.3. Therapeutic Area Outlook
  • 2.2.4. End User outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Digital Biomarker Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Digital Biomarker Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Digital Biomarker Market: Type Estimates & Trend Analysis

• 4.1. Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Digital Biomarker Market Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Wearable
    • 4.4.1.1. Wearable market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Mobile based applications
    • 4.4.2.1. Mobile based applications market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Sensors
    • 4.4.3.1. Sensors market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Others
    • 4.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Digital Biomarker Market: Clinical Practice Estimates & Trend Analysis

• 5.1. Clinical Practice Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Digital Biomarker Market Clinical Practice Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Diagnostic digital biomarkers
    • 5.4.1.1. Diagnostic digital biomarkers market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Monitoring digital biomarkers
    • 5.4.2.1. Monitoring digital biomarkers market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Predictive and Prognostic digital biomarkers
    • 5.4.3.1. Predictive and Prognostic digital biomarkers market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Others (Safety, Pharmacodynamics/ Response, Susceptibility)
    • 5.4.4.1. Others (Safety, Pharmacodynamics/ Response, Susceptibility) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Digital Biomarker Market: Therapeutic Area Estimates & Trend Analysis

• 6.1. Therapeutic Area Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Digital Biomarker Market by Therapeutic Area Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Cardiovascular and metabolic disorders (CVMD)
    • 6.4.1.1. Cardiovascular and metabolic disorders (CVMD) market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Respiratory diseases
    • 6.4.2.1. Respiratory diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Psychiatric disorders
    • 6.4.3.1. Psychiatric disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Sleep & movement disease
    • 6.4.4.1. Sleep & movement disease market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Neurological disorders
    • 6.4.5.1. Neurological disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Musculoskeletal disorders
    • 6.4.6.1. Musculoskeletal disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Others (Diabetes, Pain Management)
    • 6.4.7.1. Others (Diabetes, Pain Management) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Digital Biomarker Market: End User Estimates & Trend Analysis

• 7.1. End User Type Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Digital Biomarker Market by End User Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Healthcare companies
    • 7.4.1.1. Healthcare companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Healthcare Providers
    • 7.4.2.1. Healthcare Providers market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Healthcare Providers
    • 7.4.3.1. Healthcare Providers market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Others (Patient, caregivers)
    • 7.4.4.1. Others (Patient, caregivers) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Digital Biomarker Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2023 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.5. North America
  • 8.5.1. North America: SWOT Analysis
  • 8.5.2. U.S.
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. Canada
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Mexico
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Europe
  • 8.6.1. Europe: SWOT Analysis
  • 8.6.2. UK
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. Germany
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. France
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Italy
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Spain
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.7. Norway
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.8. Sweden
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.9. Denmark
    • 8.6.9.1. Key country dynamics
    • 8.6.9.2. Regulatory framework
    • 8.6.9.3. Competitive scenario
    • 8.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Asia Pacific: SWOT Analysis
  • 8.7.2. Japan
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. China
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. India
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.5. Australia
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.6. South Korea
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.7. Thailand
    • 8.7.7.1. Key country dynamics
    • 8.7.7.2. Regulatory framework
    • 8.7.7.3. Competitive scenario
    • 8.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. Latin America
  • 8.8.1. Latin America: SWOT Analysis
  • 8.8.2. Brazil
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.3. Argentina
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.9. MEA
  • 8.9.1. MEA: SWOT Analysis
  • 8.9.2. South Africa
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.3. Saudi Arabia
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.4. UAE
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.5. Kuwait
    • 8.9.5.1. Key country dynamics
    • 8.9.5.2. Regulatory framework
    • 8.9.5.3. Competitive scenario
    • 8.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. Company Market Position Analysis, 2023
  • 9.3.2. ActiGraph LLC
    • 9.3.2.1. Company overview
    • 9.3.2.2. Financial performance
    • 9.3.2.3. Product benchmarking
    • 9.3.2.4. Strategic initiatives
  • 9.3.3. AliveCor Inc.
    • 9.3.3.1. Company overview
    • 9.3.3.2. Financial performance
    • 9.3.3.3. Product benchmarking
    • 9.3.3.4. Strategic initiatives
  • 9.3.4. Koneksa
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Altoida Inc.
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Amgen Inc.
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Biogen Inc.
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Empatica Inc.
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Vivo Sense
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. IXICO plc
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Adherium Limited
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. Vivo Sense
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Neurotrack Technologies, Inc.
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Product benchmarking
    • 9.3.13.4. Strategic initiatives
  • 9.3.14. Aural Analytic
    • 9.3.14.1. Company overview
    • 9.3.14.2. Financial performance
    • 9.3.14.3. Product benchmarking
    • 9.3.14.4. Strategic initiatives
  • 9.3.15. Huma Therapeutics
    • 9.3.15.1. Company overview
    • 9.3.15.2. Financial performance
    • 9.3.15.3. Product benchmarking
    • 9.3.15.4. Strategic initiatives
  • 9.3.16. Sonde Health, Inc.
    • 9.3.16.1. Company overview
    • 9.3.16.2. Financial performance
    • 9.3.16.3. Product benchmarking
    • 9.3.16.4. Strategic initiatives
  • 9.3.17. Clario
    • 9.3.17.1. Company overview
    • 9.3.17.2. Financial performance
    • 9.3.17.3. Product benchmarking
    • 9.3.17.4. Strategic initiatives
  • 9.3.18. Imagene AI
    • 9.3.18.1. Company overview
    • 9.3.18.2. Financial performance
    • 9.3.18.3. Product benchmarking
    • 9.3.18.4. Strategic initiatives
  • 9.3.19. Brainomix
    • 9.3.19.1. Company overview
    • 9.3.19.2. Financial performance
    • 9.3.19.3. Product benchmarking
    • 9.3.19.4. Strategic initiatives
  • 9.3.20. Kinsa Inc.
    • 9.3.20.1. Company overview
    • 9.3.20.2. Financial performance
    • 9.3.20.3. Product benchmarking
    • 9.3.20.4. Strategic initiatives